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 In Lundbeck the Eighth Circuit affirmed a district court’s decision approving a 
merger of the only two drugs authorized to treat a rare but serious heart condition in 
infants.1  When the acquisition occurred Lundbeck owned a patented drug called 
Indocin IV, which at the time was the only drug approved by the FDA to treat this 
condition.  It then acquired the rights to NeoProfen, a drug that had been developed but 
was still awaiting FDA approval.   The two drugs were not bioequivalents, and had 
different ingredients and side effects. When approval was granted Lundbeck introduced 
the new drug at a price some 1300% higher than the price of its older drug Indocin IV, 
and also raised the price of Indocin IV to about the same level.2  Generic alternatives to 
Indocin IV became available in 2010, but until that time Lundbeck owned all approved 
drugs for treating this condition.3   Prior to the acquisition Merck, the former owner of 
Indocin IV, had charged $77.77 per treatment.  After it owned both drugs Lundbeck 
raised the price of Indocin IV to $1614.44 and the price of NeoProfen was set at $1450 
per treatment, eventually rising to $1522.50.  Prior to its approva,l the price of 
NeoProfen had been forecast at roughly $450 to $500 per treatment; however, this was 
in an environment in which the price of Indocin IV was under $80.4 
 
 The district court rejected the FTC’s challenge to the acquisition after holding that 
the two drugs must be shown to be in the same product market, and that the FTC had 
not carried its burden on this issue.5  The court heard testimony from hospital officials 
and other experts that hospitals would have been able to force price competition 
between the two drugs if they had been independently owned, as well as experts who 
disagreed.6   The court credited the testimony of the latter, concluding that there would 
not have been effective price competition between the two drugs even if they had been 
owned by different firms.7  The district court also listened to the testimony of several 
                     
*
 Ben V. & Dorothy Willie Professor of Law, University of Iowa. 
1
 FTC v. Lundbeck, Inc., 650 F.3d 1236 (8
th
 Cir. 2011).  The heart condition, called “patent 
ductus arteriosus (PDA) primarily affects low birthweight babies.  The recommended treatments 
were the drugs in question as a first line treatment, and surgery as an alternative. 
2








 See Ibid., fact finding ¶95. 
7
 The district court also observed: 
As of March 2009, of the hospitals in the United States that purchased either NeoProfen 
or Indocin IV, 51% purchased only Indocin IV; approximately 42% purchased both 
Indocin IV and NeoProfen; and approximately 5% purchased only NeoProfen. The 
remainder is unknown. Indocin IV accounts for approximately 60% and NeoProfen 
accounts for approximately 40% of the Indocin IV and NeoProfen used in the United 
States. 
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neonatologists at various hospitals and other facilities who were involved in drug use or 
purchase decisions.  Some testified that in their view NeoProfen was safer and that they 
used it almost exclusively.  Others testified that they believed both drugs were 
acceptable.  Some physicians testified that the cost of a drug did not factor into their 
treatment decisions.  Some testified that they were not even aware of drug costs when 
they made treatment decisions.  Finally, the district court also heard but was apparently 
unpersuaded by evidence that in its marketing development plans Lundbeck used a 
color coded red-yellow-green system to divide customers into groups based on their 
perceived commitment to one or the other drug, with the yellow group in the middle 
deemed to be customers who were in play for both drugs.8 
 
 The district court appeared to assume that those testifying that drug pricing was 
irrelevant or unimportant to their decision were ―right,‖ while those testifying that they 
regarded the two drugs as competing were testifying inconsistently and thus were 
―wrong.‖   But product differentiated markets do not work in that fashion.  Different 
customers make decisions for different reasons.  Some may be extremely sensitive to 
price, while others are not.  Further, often the fickleness of a fairly small number suffices 
to make a price increase unprofitable.  It is quite possible, for example, that in response 
to Alpha product’s price increase, only 20% of marginal customers would switch to a 
differentiated product Beta,9 while the remaining 80% would not switch.  However, the 
price increase could still be unprofitable if the loss from the switchers exceeded the 
gains from the nonswitchers.  This is particularly likely to be true if price/cost margins 
are very high, as they were in this case.10  Eighty percent of the customers could testify 
that they would not switch, but the two drugs would still be competitors.  In this case the 
dramatic price increases alone were sufficient evidence of decreased competitive 
pressure to justify condemning a merger that did not even arguably produce any 
efficiencies. 
 
 Customer testimony about product decisions is generally unreliable.11  Such 
questioning seldom reveals more than snapshots of a person’s immediate instincts, 
while pricing pressure operates over more extended time periods and forces buyers to 
rank other priorities.  This is particularly likely in cases involving third party payors, who 
might make adjustments in drug assignment and payout protocols only after a periodic 
                     
8
 See Brief for Plaintiffs-Appellants FTC and State of Minnesota, FTC v. Lundbeck, Inc. 2010 
WL 5558180 (Dec. 27, 2010) at *37.  The district court did not mention the color coding system.   
9
 The FTC noted that such marginal customers existed.  See id. at *25, *36-37.  See id. at 38: 
“Even where cross-elasticity is low, a single company owning the only two alternatives has the 
ability and incentive to profitably raise price, because it recaptures the revenues from sales lost 
by one product to the other.” 
10
 For example, suppose that costs are $10 and the price is $85, producing 100 sales.  The firm 
than raises the price to $100 and loses only 20 sales, while the remaining 80 pay the higher price.  
Profits before the switch are $75 X 100, or $7500.  Profits after the switch are $90 X 80, or 
$7200.  By acquiring the product to which the substitutors switched the firm would be able to 
recapture all or a significant part of these losses. 
11
 See 2B PHILLIP E. AREEDA AND HERBERT HOVENKAMP, ANTITRUST LAW ¶538b (3d ed. 2007).  
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review process.  Nonetheless, some and perhaps most health insurers and other health 
plans use methods to steer physicians toward more cost effective drugs.12  In this case, 
the price increases that followed the acquisition were market evidence far more 
convincing than anything that testimony could provide. 
 
 Customer testimony is particularly unreliable when products are differentiated, 
because different customers respond differently to relative price changes.  The result is 
that one customer’s testimony cannot be used as a surrogate for that of other 
customers.  A small sample of customers, such as those who testified in Ludbeck, could 
truthfully testify that they would not switch.  Yet a merger that eliminated a close 
substitute could produce a significant price increase by eliminating the choices of other 
customers. 
 
 The following statement in the district court’s decision indicates that the court did 
not appreciate the difference between price setting in differentiated and undifferentiated 
markets: 
 
 Were NeoProfen and Indocin IV in the same product market, Lundbeck's attempt 
to persuade neonatologists to switch from Indocin IV to NeoProfen would not 
make sense.13 
 
It might well be true in the market for an undifferentiated product such as cement, 
persuading a customer to switch from one producer to another would not make sense.  
But that is hardly the case of differentiated products.  For example, Mercedes and BMW 
are very likely in the same product market for antitrust purposes, but individual 
customers may have enthusiastic preferences for one of them or the other.  As a result 
car dealers persuade vigorously for their business.  The presence of even a minority of 
customers who are sensitive to price and prepared to switch may substantially limit the 
ability of one to raise prices.   In sum, all of those testifying on the issue could have 
been correct but the two products were still in the same market, as the pricing evidence 
indicates.  Indeed, one might say the same thing that the district court said about 
Lundbeck’s color coding system.  If no customers regarded the two drugs as substitutes 
it would not make sense for Lundbeck to monitor the vulnerability of customers to 
switching among the two drugs. 
 
 As the Eighth Circuit described the relationship between the acquisition and the 
price increase: 
 
According to Lundbeck's internal documents, it anticipated that a dramatic price 
increase of Indocin IV would draw generic competitors into the market. As a 
result, it ceased promoting Indocin IV, focusing instead on increasing the market 
                     
12
 See, e..g, http://www.oregon.gov/OHA/healthplan/tools_prov/pdl.shtml (describing Oregon 
Health Plan preferred drug list); http://www.shpnc.org/myPharmacyBenefits/default.aspx 
(similar, North Carolina); http://cchealth.org/health_plan/pdl.php (similar; Contra Costa Health 
Services Plan). 
13
 Lundbeck, 2010 WL 3810015, fact finding ¶116. 
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share of NeoProfen—as a superior PDA treatment. The FTC argues that this 
business strategy—to market NeoProfen as better than Indocin IV—means that 
Lundbeck viewed NeoProfen as a direct competitor to Indocin IV, and thus the 
drugs must be in the same product market. However, Lundbeck's strategy to 
discontinue promoting Indocin IV in favor of NeoProfen can also be interpreted to 
mean that while Indocin IV was vulnerable to generics, NeoProfen was not, and 
thus the products are not interchangeable. If there are two permissible views of 
evidence, the factfinder's choice between them is not clearly erroneous.14 
 
 But the alternative strategy that the Eighth Circuit described and that the district 
court accepted was just as anticompetitive as the FTC’s theory.  Lundbeck, facing the 
prospect that its existing drug was susceptible to generic entry, acquired the newer 
drug, stopped promoting its older drug in order to induce users to switch, and began 
charging a much higher price for the newer drug, given the lack of  price competition 
from the older one.  That scenario makes the merger no less harmful. 
 In any event, if the two drugs were not in the same relevant market, then each 
one was very likely a monopoly, because the two were the only drugs approved for the 
heart condition in question.  While surgery was an option, it would use radically different 
technologies, and in this case the drugs were clearly the preferred course of action.15 
 
 A monopolist’s acquisition of a nascent rival is just as much a source of 
competitive concern as a merger of two firms currently producing in the same market.16  
To be sure, a dominant firm may sometimes require the productive assets of a nascent 
rival in order to improve its own technology or keep it up to date.  Extreme care must be 
taken, however, lest such acquisitions become devices for shutting out the only viable 
avenues toward greater competition.  For that reason a monopolist should be permitted 
to acquire only a nonexclusive license to a patent within the area of its power.17   In this 
case there was no claim to be made that the defendant’s acquisition of the second drug 
was necessary for efficient production or distribution.  The acquisition plus the 
subsequent price increases indicated that its only purpose was to prevent competition 
with a nascent rival and prolong a dominant position in the face of possibly increasing 
                     
14




 That is to say, one must not commit the “Cellophane” fallacy of putting the drugs and the 
surgery in the same market simply because they exhibited some substitution for one another, but 
without considering whether current prices are already well above cost.  Presumptively, products 
using significantly different technologies belong in different markets.  See 2B Antitrust Law 
¶539.  See also United States v. H&R Block, Inc., ___ F.Supp.2d ___, 2011 WL 5438955 
(D.D.C., November 10, 2011) (computer tax preparation programs not in same market as 
commercial tax preparation services). 
16
 See 4 PHILLIP E. AREEDA & HERBERT HOVENKAMP, ANTITRUST LAW ¶912 (3d ed. 2009)  
17
 See 3 id., ¶707g (3d ed. 2008) 




 The court also rejected the use of what it termed a ―hypothetical‖ market in which 
the merger had not occurred.19  In fact, however, all merger analysis involves the use of 
hypothetical markets that postulate alternatives in which the merger did or did not occur.  
The ―may … substantially lessen competition‖ standard in §7 of the Clayton Act 
contemplates that the fact finder must consider movement from the situation that 
currently exists to a hypothetical one that would otherwise exist.  If the case involves a 
pre-acquisition challenge, then the hypothetical market is the one in which the merger 
has occurred; if it involves a post-acquisition challenge such as this one, then the 
hypothetical market is the one prior to the merger.  That is to say, the word ―lessen‖ 
implies movement, and one cannot assess movement without hypothesizing a position 
that is different from the current one. 
 
 Finally, the Lundbeck decision yields the perverse result that it makes 
condemnation of a merger more difficult in precisely the situations where the market is 
less sensitive to price increases – namely, where the decisions are made by persons 
who are not sensitive to pricing.  Although the physicians who write prescriptions are not 
out of pocket and many may be insensitive to price in the short run, eventually they will 
respond to the pressures imposed by insurers, other prepaid health care providers, and 





 Most mergers that are subject to challenge occur in markets that exhibit some 
degree of product differentiation.  The analytic problems of the Lundbeck case lie 
principally in an attempt to use a model of perfect competition in a setting where it does 
not apply.  The fact that the two drugs at issue in Lundbeck were not identical 
bioequivalent competitors suggests strongly that user responses will be arrayed over 
time and space in a complex fashion.  This is not a situation in which virtually all 
customers immediately drop one brand in response to the other’s price cut, or where 
none of them does.  As soon as we know that differentiation exists it makes little sense 
to state categorically that two products are not in the same market until we can 
ascertain with some certainty that the demand for one is unresponsive – across the full 
range of consumers – to the price of the other.  As soon as we know that some 
customers are on the margin, however, then it becomes necessary to determine 
                     
18
 The strategy resembles one used via tying when a dominant firm in a current technology tries 
to roll that position into one of dominant in a successor technology.  See 9 PHILLIP E. AREEDA & 
HERBERT HOVENKAMP, ANTITRUST LAW ¶1703d, 1729d2 (3d ed. 2011). 
19
 Lundbeck, 650 F.3d at 1240-1241 & n.3. 
20
 See the websites mentioned in note __, supra; and see Robert N. Sahr, The Biologics Price 
Competition and Innovation Act: Innovation Must come Before Price Competition, 2009 B.C. 
INTELL. PROP. & TECH. FORUM 070201 (July 19, 2009) (summarizing state laws compelling 
generic substitution); 
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whether they are a sufficient constraint on pricing to warrant merger concern.   The 
post-merger price increase in this case provides a clear answer.  In a situation such as 
Lundbeck, where the drug treatments in question were the only two available options 
and price/cost margins were very high, condemnation should have been an easy call. 
